Point72 Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Point72 Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-100,000	Closed	-$20.4M	–	1162
2019 Q4	$20.4M	Buy	+100,000	New	+$18.2M	0.11%	255

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Point72 Asset Management's RETA Position: Q3 2023 in Review

Point72 Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 568,151 shares — an estimated $57.9M sold.

Point72 Asset Management first reported a position in RETA in Q2 2018 and held it in 14 quarters. The position peaked at $61.3M in Q3 2018. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Point72 Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Point72 Asset Management sold 568,151 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $57.9M.
Point72 Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 14 quarters.
Point72 Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $61.3M in Q3 2018.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Point72 Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.